These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25416196)

  • 1. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
    Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
    Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
    Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K
    Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
    Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
    Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
    Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
    Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
    Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
    Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
    Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
    Kamen BA; Smith AK
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-
    Hou Z; Gattoc L; O'Connor C; Yang S; Wallace-Povirk A; George C; Orr S; Polin L; White K; Kushner J; Morris RT; Gangjee A; Matherly LH
    Mol Cancer Ther; 2017 May; 16(5):819-830. PubMed ID: 28138029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
    Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
    Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
    [No Abstract]   [Full Text] [Related]  

  • 14. Folate Receptor α-Targeted
    Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
    Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
    Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.
    Furuuchi K; Rybinski K; Fulmer J; Moriyama T; Drozdowski B; Soto A; Fernando S; Wilson K; Milinichik A; Dula ML; Tanaka K; Cheng X; Albone E; Uenaka T
    Cancer Sci; 2021 Jun; 112(6):2467-2480. PubMed ID: 33756060
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Altwerger G; Bonazzoli E; Bellone S; Egawa-Takata T; Menderes G; Pettinella F; Bianchi A; Riccio F; Feinberg J; Zammataro L; Han C; Yadav G; Dugan K; Morneault A; Ponte JF; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Mol Cancer Ther; 2018 May; 17(5):1003-1011. PubMed ID: 29440294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Manning-Geist BL; Sullivan MW; Zhou Q; Iasonos A; Selenica P; Stallworth C; Liu YL; Long Roche K; Gordhandas S; Aghajanian C; Chi D; O'Cearbhaill R; Grisham RN; Chui MH
    Gynecol Oncol; 2024 Sep; 188():52-57. PubMed ID: 38941962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
    Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
    Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.